References
- Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29(5):385–396.
- Medicines and vaccines post-market vigilance - statistics for 2017 2018 [updated 2018 Aug 10]. Available from: https://www.tga.gov.au/medicines-and-vaccines-post-market-vigilance-statistics-2017
- Ribeiro A, Lima S, Zampieri ME, et al. Filling quality of the reports of adverse drug reactions received at the Pharmacovigilance Centre of Sao Paulo (Brazil): missing information hinders the analysis of suspected associations. Expert Opin Drug Saf. 2017;16(12):1329–1334.
- Plessis L, Gomez A, Garcia N, et al. Lack of essential information in spontaneous reports of adverse drug reactions in Catalonia-a restraint to the potentiality for signal detection. Eur J Clin Pharmacol. 2017;73(6):751–758.
- Lopez-Gonzalez E, Herdeiro MT, Figueiras A. Determinants of under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2009;32(1):19–31.
- Mirbaha F, Shalviri G, Yazdizadeh B, et al. Perceived barriers to reporting adverse drug events in hospitals: a qualitative study using theoretical domains framework approach. Implement Sci. 2015;10:110.
- Nita Y, Batty KT, Plumridge RJ. Adverse drug reaction reporting: attitudes of australian hospital pharmacists and doctors. J Pharm Pract Res. 2005;35(1):9–14.
- Varallo FR, Guimaraes Sde O, Abjaude SA, et al. [Causes for the underreporting of adverse drug events by health professionals: a systematic review]. Rev Esc Enferm USP. 2014;48(4):739–747.
- Herdeiro MT, Figueiras A, Polonia J, et al. Physicians’ attitudes and adverse drug reaction reporting: a case-control study in Portugal. Drug Saf. 2005;28(9):825–833.
- Li R, Curtain C, Bereznicki L, et al. Community pharmacists’ knowledge and perspectives of reporting adverse drug reactions in Australia: a cross-sectional survey. Int J Clin Pharm. 2018;40(4):878–889.
- Gahr M, Eller J, Connemann BJ, et al. Underreporting of adverse drug reactions: results from a survey among physicians. Eur Psychiatry. 2017;41:S369.
- Black Triangle Scheme: Australian Government Department of Health Therapeutic Goods Administration; 2018 [updated 2018 Jul 19]. Available from: https://www.tga.gov.au/black-triangle-scheme
- Medicines under additional monitoring: European Medicines Agency; 2014 [cited 2020 Mar 25]. Available from: https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/medicines-under-additional-monitoring
- Belton KJ, Lewis SC, Payne S, et al. Attitudinal survey of adverse drug reaction reporting by medical practitioners in the United Kingdom. Br J Clin Pharmacol. 1995;39(3):223–226.
- Thorne RJ, Bruggink RJ, Kelly SJ, et al. Awareness and compliance with pharmacovigilance requirements amongst UK oncology healthcare professionals. Ecancermedicalscience. 2018;12:809.
- Cook J. Global pharmacovigilance networks: a regulator’s perspective. Canberra, Australia: Australian Government Department of Health: Therapeutic Goods Administration; 2018.
- Pharmacovigilance responsibilities of medicine sponsors - Australian recommendations and requirements: Australian government department of health: therapeutic goods administration 2018 [cited 2020 Mar 25]. Available from: https://www.tga.gov.au/publication/pharmacovigilance-responsibilities-medicine-sponsors
- Adverse event reporting - adverse event management system: Australian department of health therapeutic goods administration; 2018 [cited 2020 Mar 25]. Available from: https://aems.tga.gov.au/
- Blue card adverse reaction reporting form: Australian department of health - therapeutic goods administration; 2019. Available from: https://www.tga.gov.au/form/blue-card-adverse-reaction-reporting-form
- CIOMS I form: council for international organisations of medical sciences; 2019 [cited 2020 Mar 25]. Available from: https://cioms.ch/cioms-i-form/
- ICH harmonized tripartite guideline clinical safety data management: definitions and standards for expedited reporting E2A: international conference on harmonization; 1994 [cited 2019]. Available from: https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2A/Step4/E2A_Guideline.pdf
- The use of the WHO-UMC system for standardised case causality assessment World Health Organisation - Uppsala Monitoring Centre. 2012 [cited 2020 Mar 25]. Available from: https://www.who.int/medicines/areas/quality_safety/safety_efficacy/WHOcausality_assessment.pdf
- World Health Organisation - members for international drug monitoring 2019 [cited 2020 Mar 25]. Available from: https://www.who-umc.org/global-pharmacovigilance/members/who-programme-members/
- Weber JCP. Epidemiology of adverse reactions to nonsteroidal anti-inflammatory drugs. Rainsford KDaV GD, editor. New York: Raven Press; 1984. p. 1–7.
- Hoffman KB, Dimbil M, Erdman CB, et al. The Weber effect and the United States Food and Drug Administration’s Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010. Drug Saf. 2014;37(4):283–294.
- Li R, Zaidi STR, Chen T, et al. Effectiveness of interventions to improve adverse drug reaction reporting by healthcare professionals over the last decade: a systematic review. Pharmacoepidemiol Drug Saf. 2020;29(1):1–8.
- Alatawi YM, Hansen RA. Empirical estimation of under-reporting in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS). Expert Opin Drug Saf. 2017;16(7):761–767.
- Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–245.
- Karch FE, Lasagna L. Toward the operational identification of adverse drug reactions. Clin Pharmacol Ther. 1977;21(3):247–254.
- Michie S, van Stralen M, West R. The behaviour change wheel: a new method for characterising and designing behaviour change interventions. Implement Sci. 2011;6:42.